Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.36 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.32 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.32 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11105 | 0.85 | PKM (0.44) | ALDH1A1HSD17B10CXCR2UCHL1SMN1; SMN2 | |
| SCHEMBL29973532 | 0.82 | KDM4E (0.42) | ALDH1A1TSHRKDM4ECXCR2ROCK1 | |
| SCHEMBL14656987 | 0.82 | KDM4E (0.42) | ALDH1A1TSHRKDM4ECXCR2ROCK1 | |
| SCHEMBL28831157 | 0.79 | MTNR1A (0.40) | CXCR2ROCK1LIPEAAK1 | |
| SCHEMBL4158920 | 0.78 | AKR1B1 (0.46) | KDM4ECXCR2ROCK1MAPTP4HB | |
| SCHEMBL29179974 | 0.76 | CXCR2 (0.40) | CXCR2ROCK1LIPEP4HB | |
| SCHEMBL1240538 | 0.76 | LIPG (0.47) | AAK1P4HB | |
| SCHEMBL23553199 | 0.76 | UCHL1 (0.34) | ALDH1A1TSHRKDM4EHPGDHSD17B10 | |
| SCHEMBL13197065 | 0.74 | GABRA1 (0.40) | CXCR2ROCK1 | |
| SCHEMBL3319492 | 0.74 | CXCR2 (0.41) | CXCR2ROCK1LIPEP4HB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3225623-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | Ventirx Pharmaceuticals, Inc. (US) | 2017-10-04 | — | — | EP | disclosed |
| US-9655904-B2 | Substituted benzoazepines as toll-like receptor modulators | VENTIRX PHARMACEUTICALS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2467377-B1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS INC (US) | 2016-12-28 | — | — | EP | disclosed |
| US-20160129010-A1 | Substituted Benzoazepines as Toll-Like Receptor Modulators | VENTIRX PHARMACEUTICALS INC (US) | 2016-05-12 | — | — | US | disclosed |
| US-9126940-B2 | Substituted benzoazepines as toll-like receptor modulators | VENTIRX PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140234376-A1 | Substituted Benzoazepines as Toll-Like Receptor Modulators | ARRAY BIOPHARMA, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| EP-2467377-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | Ventirx Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20110092485-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| WO-2011022508-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234376-A1 | Substituted Benzoazepines as Toll-Like Receptor Modulators | TLR8, TLR1, TLR7 | ALDH1A1 1667/4885TSHR 2731/4885KDM4E 333/4885 |
| US-20160129010-A1 | Substituted Benzoazepines as Toll-Like Receptor Modulators | TLR8, TLR7, TLR9 | ALDH1A1 2553/4885TSHR 2218/4885KDM4E 925/4885 |
| US-20110092485-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | TLR8, TLR1, TLR7 | ALDH1A1 1667/4885TSHR 2731/4885KDM4E 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.